Navigation

Medically assisted alcohol withdrawal - drug regimens

Quality statement

People needing medically assisted alcohol withdrawal receive medication using drug regimens appropriate to the setting in which the withdrawal is managed in accordance with NICE guidance.

Quality measure

Structure: Evidence of local arrangements to ensure that people undergoing medically assisted alcohol withdrawal are prescribed medication that is administered using drug regimens in accordance with NICE clinical guideline 115 and NICE clinical guideline 100.

Process

a) Proportion of people undergoing planned medically assisted alcohol withdrawal who receive medication using drug regimens in accordance with NICE clinical guideline 115.

Numerator - the number of people in the denominator receiving medication using drug regimens in accordance with NICE clinical guideline 115.

Denominator - the number of people undergoing medically assisted alcohol withdrawal.

b) Proportion of people in acute (unplanned) alcohol withdrawal who receive medication using drug regimens in accordance with NICE clinical guideline 100.

Numerator - the number of people in the denominator receiving medication using drug regimens in accordance with NICE clinical guideline 100.

Denominator - the number of people in acute (unplanned) alcohol withdrawal.

Outcome

Proportion of people undergoing medically assisted alcohol withdrawal (planned or unplanned) who complete withdrawal successfully and without complications.

Numerator - the number of people in the denominator completing medically assisted withdrawal successfully and without complications.

Denominator - the number of people undergoing medically assisted alcohol withdrawal (planned or unplanned).

Description of what the quality statement means for each audience

Service providers ensure that people undergoing planned medically assisted alcohol withdrawal are prescribed medication that is administered using drug regimens in accordance with NICE clinical guideline 115 and people in acute (unplanned) withdrawal are prescribed medication that is administered using drug regimens in accordance with NICE clinical guideline 100.

Healthcare professionals caring for people undergoing planned medically assisted alcohol withdrawal ensure they use drug regimens in accordance with NICE clinical guideline 115 and, for people in acute (unplanned) withdrawal, use drug regimens in accordance with NICE clinical guideline 100.

Commissioners ensure they commission services for planned medically assisted alcohol withdrawal that use drug regimens in accordance with NICE clinical guideline 115 and for people in acute (unplanned) withdrawal, that use drug regimens in accordance with NICE clinical guideline 100.

People undergoing medically assisted alcohol withdrawal are given medication in a manner (frequency and amount) determined by the place where withdrawal is carried out.

Source clinical guideline references

NICE clinical guideline 115 section 1.3.5, recommendation 1.3.7.6 and NICE clinical guideline 100 recommendations 1.1.3.1 and 1.1.3.4.

Data source

Structure

Local data collection.

Process

a) Local data collection. Prescription of clomethiazole (which should not be offered for community-based withdrawal) is contained within NICE clinical guideline 115: audit support criterion 7.

b) Local data collection. Contained within NICE clinical guideline 100: audit support criteria 3 and 4.

The NHS Information Centre statistics on alcohol in England reports on items prescribed for the treatment of alcohol dependence, including the setting in which they are prescribed.

Outcome: Local data collection. The International statistical classification of diseases and related health problems (ICD-10) code for alcohol withdrawal state with delirium is F10.4.

Definitions

All prescribing for medically assisted alcohol withdrawal should be carried out in accordance with NICE clinical guideline 115 section 1.3.5, recommendation 1.3.7.6 and NICE clinical guideline 100 recommendations 1.1.3.1 and 1.1.3.4 on drug regimens for assisted withdrawal.

Prescribers should use each drug's summary of product characteristics (SPC) with regard to current licensed indications, contraindications and special considerations to inform their decision about a person they are prescribing for. If a drug is used at a dose or for an application that does not have UK marketing authorisation, informed consent should be obtained and documented.

This page was last updated: 25 August 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.